Correlation between serum cryptococcal antigen titre and meningitis in immunocompetent patients

References

1. Nguyen MH, Husain S, Clancy CJ, Peacock JE, Hung CC et al. Outcomes of central nervous system cryptococcosis vary with host immune function: results from a multi-center, prospective study. J Infect 2010; 61:419–426 [View Article][PubMed]
   [Google Scholar]
2. Heitman J. Cryptococcus: From Human Pathogen to Model Yeast Washington: ASM Press; 2011
   [Google Scholar]
3. Gassiep I, McDougall D, Douglas J, Francis R, Playford EG. Cryptococcal infections in solid organ transplant recipients over a 15-year period at a state transplant center. Transpl Infect Dis 2017; 19:e12639 [View Article]
   [Google Scholar]
4. Bratton EW, El Husseini N, Chastain CA, Lee MS, Poole C et al. Comparison and temporal trends of three groups with cryptococcosis: HIV-infected, solid organ transplant, and HIV-negative/non-transplant. PLoS One 2012; 7:e43582 [View Article][PubMed]
   [Google Scholar]
5. Chen SC. Australasian Society for Infectious Diseases (ASID) Mycoses Iterest Group Cryptococcosis in Australasia and the treatment of cryptococcal and other fungal infections with liposomal Amphotericin B. J Antimicrob Chemother 2002; 49:57–61 [View Article][PubMed]
   [Google Scholar]
6. Chen SC, Slavin MA, Heath CH, Playford EG, Byth K et al. Clinical manifestations of Cryptococcus gattii infection: determinants of neurological sequelae and death. Clin Infect Dis 2012; 55:789–798 [View Article][PubMed]
   [Google Scholar]
7. Aye C, Henderson A, Yu H, Norton R. Cryptococcosis-the impact of delay to diagnosis. Clin Microbiol Infect 2016; 22:632–635 [View Article][PubMed]
   [Google Scholar]
8. Gassiep I, Douglas J, Emeto TI, Crawley K, Playford EG. Cryptococcal infections over a 15 year period at a tertiary facility & impact of guideline management. Mycoses 2018; 61:633–638 [View Article]
   [Google Scholar]
9. Jarvis JN, Lawn SD, Vogt M, Bangani N, Wood R et al. Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis 2009; 48:856–862 [View Article][PubMed]
   [Google Scholar]
10. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46:1813–1821 [View Article][PubMed]
    [Google Scholar]
11. Klein KR, Hall L, Deml SM, Rysavy JM, Wohlfiel SL et al. Identification of Cryptococcus gattii by use of L-canavanine glycine bromothymol blue medium and DNA sequencing. J Clin Microbiol 2009; 47:3669–3672 [View Article][PubMed]
    [Google Scholar]
12. Westblade LF, Jennemann R, Branda JA, Bythrow M, Ferraro MJ et al. Multicenter study evaluating the Vitek MS system for identification of medically important yeasts. J Clin Microbiol 2013; 51:2267–2272 [View Article][PubMed]
    [Google Scholar]
13. Baddley JW, Perfect JR, Oster RA, Larsen RA, Pankey GA et al. Pulmonary cryptococcosis in patients without HIV infection: factors associated with disseminated disease. Eur J Clin Microbiol Infect Dis 2008; 27:937–943 [View Article][PubMed]
    [Google Scholar]
14. Lu CH, Chang WN, Chang HW, Chuang YC. The prognostic factors of cryptococcal meningitis in HIV-negative patients. J Hosp Infect 1999; 42:313–320 [View Article][PubMed]
    [Google Scholar]
15. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis 2010; 50:291–322 [View Article][PubMed]
    [Google Scholar]
16. Jitmuang A, Panackal AA, Williamson PR, Bennett JE, Dekker JP et al. Performance of the Cryptococcal Antigen Lateral Flow Assay in Non-HIV-Related Cryptococcosis. J Clin Microbiol 2016; 54:460–463 [View Article][PubMed]
    [Google Scholar]